TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

CPO

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: US

Quick snapshot

CPO

ST13

US500000079317618

Class

5

Filing

79317618

Registration

7050981

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

42

Latest update

09/12/2023

Classification

Registered

Trademark type

Combined

Nice classes

5

Filing date

04/22/2021

Registration date

05/16/2023

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

05/16/2023

Last transaction

05/16/2023

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

3

Owner type

99

Owner location

AU

Examiner

CORNWELL, ANDREA B

Law office

M60

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the stylized wording "CPO" to the right of a stylized concentric oval and circle design.

Holders and representatives

Holders

Pharmako Biotechnologies Pty Limited

Representatives

Jennifer A. Visintine Thompson Coburn LLP

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Medicines in tablet form for the treatment of nutritional and vitamin deficiencies; medicated preparations in the form of powders, namely, drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; veterinary preparations in the form of powder, namely, drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of veterinary pharmaceuticals; veterinary preparations, namely, dietary and nutritional supplements for veterinary use; medical preparations, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; medicated food additives being pharmaceutical products that facilitate or increase the absorption of vitamins and minerals; medicated supplements for foodstuffs for animals; medicated supplements for foodstuffs for human consumption for medical purposes; medicated skin care preparations; medicated preparations for use as supplements for food for medical purposes; powders for skin care for medical use; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; medicinal oils containing vitamins and minerals; oils adapted for pharmaceutical purposes, namely, for the increasing the bioavailability and absorption of active ingredients in foodstuffs and medicines; oils for use in medicine, namely, medicated oils containing vitamins and minerals; dietary supplements; pharmaceutical preparations, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; dietetic foods adapted for medical purposes; dietetic substances namely foods, beverages and supplements adapted for medical use; dietetic substances, namely foods, beverages and supplements for veterinary use; dietary supplements; dietary supplements for animals; nutritional meal replacements, namely beverages and supplements adapted for medical use; nutritional preparations for medical use, namely, medications used for the delivery and absorption of nutrients; nutritional supplements; medicinal healthcare products, namely, dietary supplements with medicinal properties that increase the bioavailability and absorption of active ingredients in foodstuffs and medicines; chemical products for use in medical or veterinary biotechnology, namely, chemical preparations for increasing bioavailability and absorption of active ingredients in foodstuffs and medicines; biotechnological preparations for medical use, namely, mixed biological preparations for the prevention and treatment of nutritional deficiencies; chemical products for medical use, namely, chemical reagents for medical purposes; dietary supplements with a cosmetic effect; medicated skin creams for personal care; medicated preparations for the regeneration of the skin; medicated preparations for the treatment of the skin; medicated preparations for use in the bath; medicated creams for the face

Publications

History of USPTO decisions and trademark events.

42 publications found

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

09/12/2023

FICS

FINAL DISPOSITION NOTICE SENT TO IB

08/17/2023

FIMP

FINAL DISPOSITION PROCESSED

08/17/2023

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

08/16/2023

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

05/16/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

05/16/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

02/28/2023

PUBO

PUBLISHED FOR OPPOSITION

02/28/2023

GPNX

NOTIFICATION PROCESSED BY IB

02/27/2023

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

02/08/2023

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

02/08/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

02/08/2023

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

02/06/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

01/26/2023

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

01/18/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

01/18/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

01/18/2023

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

01/18/2023

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

01/18/2023

NREP

NEW REPRESENTATIVE AT IB RECEIVED

09/17/2022

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

07/28/2022

GNFR

FINAL REFUSAL E-MAILED

07/28/2022

CNFR

FINAL REFUSAL WRITTEN

07/28/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

07/14/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

07/13/2022

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

07/13/2022

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

07/08/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

07/08/2022

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

07/08/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

07/08/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

07/08/2022

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

07/08/2022

RFNT

REFUSAL PROCESSED BY IB

01/30/2022

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

01/13/2022

RFRR

REFUSAL PROCESSED BY MPU

01/13/2022

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

12/22/2021

CNRT

NON-FINAL ACTION WRITTEN

12/21/2021

DOCK

ASSIGNED TO EXAMINER

12/17/2021

MAFR

APPLICATION FILING RECEIPT MAILED

08/24/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/18/2021

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

08/16/2021

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

08/12/2021

Continuous trademark protection

Get notified about every new filing that threatens CPO or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.